Intriguingly, PIP5K1A has been recently shown to interact directly with mutant KRAS and TP53, which were the most prevalent drivers in lung cancer, and facilitated downstream oncogenic signaling (Adhikari and Counter, 2018; Choi et al., 2019). This evidence concerns the gene KRAS and lung carcinoma.